Baader Bank Aktiengesellschaft Takes Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Baader Bank Aktiengesellschaft acquired a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 4,500 shares of the company’s stock, valued at approximately $249,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. R Squared Ltd bought a new position in shares of Tarsus Pharmaceuticals in the fourth quarter worth $53,000. FMR LLC boosted its position in shares of Tarsus Pharmaceuticals by 236.6% in the third quarter. FMR LLC now owns 5,032 shares of the company’s stock valued at $166,000 after acquiring an additional 3,537 shares during the period. SG Americas Securities LLC grew its stake in Tarsus Pharmaceuticals by 87.5% during the third quarter. SG Americas Securities LLC now owns 7,242 shares of the company’s stock valued at $238,000 after acquiring an additional 3,379 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Tarsus Pharmaceuticals by 64.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,317 shares of the company’s stock worth $241,000 after acquiring an additional 2,879 shares during the period. Finally, Hsbc Holdings PLC purchased a new stake in Tarsus Pharmaceuticals in the 2nd quarter worth approximately $241,000. 90.01% of the stock is currently owned by institutional investors.

Tarsus Pharmaceuticals Stock Performance

TARS opened at $51.74 on Friday. The business’s fifty day simple moving average is $51.50 and its 200 day simple moving average is $39.58. Tarsus Pharmaceuticals, Inc. has a 52 week low of $20.08 and a 52 week high of $57.14. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on TARS shares. Oppenheimer upped their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. The Goldman Sachs Group upped their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research note on Friday, November 15th. Finally, Barclays lifted their price target on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research report on Monday. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $56.00.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.